Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06841354 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06841354 · ClinicalTrials.gov record · last posted 2026-08-21

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

StatusRecruiting
PhasePhase 3
Started2025-03-16
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.

Amendment record 51 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 51 times since 2025-02-18; most recent amendment 2026-07-24. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-04-07
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT06841354
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Triple Negative Breast Neoplasms
Enrollment 1,000 participants
Start Date 2025-03-16
Primary Completion 2030-05-18 (estimated)
Study Completion 2030-05-18 (estimated)
Updated on ClinicalTrials.gov 2026-08-21